Retatrutide: The Next Generation of GLP-1 Treatment
Retatrutide is a triple hormone receptor agonist showing unprecedented weight loss in clinical trials. Learn how it works, the latest trial data, and when it might be available.
Retatrutide has generated enormous excitement in the obesity medicine community. As a triple receptor agonist, it represents a fundamentally new approach that goes beyond current GLP-1 medications.
What Is Retatrutide?
Retatrutide (LY3437943) is a triple incretin receptor agonist developed by Eli Lilly. It activates three receptors simultaneously:
- GLP-1 receptor - Reduces appetite, slows gastric emptying (same as semaglutide/tirzepatide)
- GIP receptor - Enhances insulin secretion, affects fat metabolism (same dual action as tirzepatide)
- Glucagon receptor - Increases energy expenditure, promotes fat breakdown, reduces liver fat
This triple mechanism means retatrutide attacks obesity from more angles than any previous medication. The glucagon component is the key differentiator - it increases the body's energy expenditure (calorie burning), which current GLP-1 and dual agonists do not significantly do.
Phase 2 Clinical Trial Results
The Phase 2 trial results, published in the New England Journal of Medicine in June 2023, were striking (Jastreboff et al., 2023):
| Dose | Weight Loss at 48 Weeks | Participants Losing >15% |
|---|---|---|
| 1mg | 8.7% | ~28% |
| 4mg | 17.1% | ~54% |
| 8mg | 22.8% | ~73% |
| 12mg | 24.2% | ~79% |
| Placebo | 2.1% | ~4% |
Key Findings
- The 24.2% weight loss at the 12mg dose exceeds any other drug studied in clinical trials to date
- Weight loss was still accelerating at the 48-week mark, suggesting even greater losses with longer treatment
- Nearly 80% of participants on the highest dose lost more than 15% of their body weight
- The drug was administered as a weekly subcutaneous injection
Comparison With Current Medications
| Medication | Mechanism | Max Weight Loss (Trials) | Trial Duration |
|---|---|---|---|
| Retatrutide | Triple (GLP-1/GIP/glucagon) | 24.2% | 48 weeks |
| Tirzepatide | Dual (GLP-1/GIP) | 22.5% | 72 weeks |
| Semaglutide | Single (GLP-1) | 14.9% | 68 weeks |
| Liraglutide | Single (GLP-1) | 8.0% | 56 weeks |
Importantly, retatrutide achieved its results in a shorter time frame (48 weeks) than tirzepatide or semaglutide trials, and the weight loss curve had not plateaued.
Benefits Beyond Weight Loss
Liver Fat Reduction
Retatrutide showed remarkable effects on liver fat. In participants with non-alcoholic fatty liver disease (NAFLD), the 12mg dose reduced liver fat by an average of 82% at 48 weeks, with over 85% of participants achieving complete resolution of fatty liver.
This is likely due to the glucagon receptor activation, which directly promotes liver fat oxidation. No current GLP-1 medication has shown such dramatic liver benefits.
Metabolic Improvements
- Significant reductions in HbA1c (diabetes marker)
- Improvements in triglycerides and cholesterol
- Reductions in blood pressure
- Decreases in inflammatory markers
Side Effects
The side effect profile was similar to other GLP-1 medications:
- Nausea: 16-25% (depending on dose)
- Diarrhea: 14-22%
- Vomiting: 9-14%
- Constipation: 8-14%
Notably, GI side effects were not dramatically higher than those seen with semaglutide or tirzepatide, despite the greater weight loss.
Heart rate increases of 2-4 beats per minute were observed, attributed to the glucagon component. This is being monitored in Phase 3 trials.
Phase 3 Trials and Timeline
Eli Lilly launched the Phase 3 programme (TRIUMPH) in late 2023. These larger trials will assess:
- Long-term efficacy and safety over 72+ weeks
- Cardiovascular outcomes
- Effects on sleep apnea, fatty liver, and other obesity-related conditions
- Comparison with placebo and potentially active comparators
Estimated timeline:
- Phase 3 results expected: 2026-2027
- Potential FDA submission: 2027
- Potential approval and launch: 2027-2028
How Will Retatrutide Fit Into Treatment?
If Phase 3 results confirm the Phase 2 data, retatrutide could become the most effective non-surgical obesity treatment available. It may be particularly beneficial for:
- Patients who have not achieved sufficient weight loss on semaglutide or tirzepatide
- People with NAFLD/MASH who need both weight loss and liver fat reduction
- Patients with significant obesity (BMI 40+) seeking maximal weight loss
The Bottom Line
Retatrutide's triple agonist mechanism represents a genuine advance in obesity pharmacotherapy. Phase 2 results showing 24% weight loss with continued acceleration are unprecedented. While it will likely be several years before approval, retatrutide may redefine what is achievable with medication-based weight loss.
In the meantime, effective GLP-1 medications are available now. Track your current treatment with GLP Pal while keeping an eye on this exciting pipeline.